Moderna Agrees $950M Upfront, $2.25B Maximum to Settle LNP Patent Lawsuit
Moderna will pay $950m upfront and up to $2.25bn total to resolve a patent infringement suit over lipid nanoparticle technology, securing a non-exclusive license for infectious disease applications. CEO Stéphane Bancel said the deal removes legacy legal risk and supports revenue growth in 2026 with breakeven by 2028.
1. Settlement Terms
Moderna will pay $950m upfront and up to $2.25bn in total to settle patent infringement claims by Genevant and Arbutus over its lipid nanoparticle delivery technology, ending all pending litigation. The agreement includes a contingent $1.3bn payment if Moderna’s Section 1498 appeal is not upheld by the US Court of Federal Claims.
2. Licensing Rights
As part of the settlement, Moderna gains a non-exclusive license to Genevant and Arbutus’ LNP technology specifically for infectious disease vaccine applications, ensuring ongoing use of the delivery platform behind its Spikevax Covid-19 vaccine.
3. Financial Impact and Outlook
CEO Stéphane Bancel noted the resolution clears legacy legal uncertainty, supports a return to revenue growth in 2026 with expected year-end cash above $5bn, and aligns with the company’s goal of achieving financial breakeven by 2028 following a Q4 2025 net loss of $826m.
4. Broader IP Landscape
This settlement concludes one of several cross-complaints in the industry, as Moderna, Pfizer and BioNTech have engaged in global patent disputes over mRNA and LNP technologies since 2022, highlighting ongoing competition for intellectual property rights in vaccine delivery platforms.